29.06.2016 • NewsElaine BurridgeSanofiBoehringer Ingelheim

Sanofi and Boehringer Ingelheim Finalize Swap

(c) Sanofi
(c) Sanofi

Following six months of negotiations, French drugmaker Sanofi and German pharmaceutical company Boehringer Ingelheim have agreed an asset swap that sees Sanofi exchanging its Merial animal health division for Boehringer’s consumer healthcare (CHC) business, excluding its activities in China. The strategic swap, a significant move in both companies’ histories and in the pharmaceutical sector, lays the foundation for both to reach size and scale in two highly attractive businesses, they said.

Both have agreed that Lyon and Toulouse in France would be key operational centers of Boehringer’s animal health business. These include business operations, R&D and manufacturing facilities in Lyon, and the production site in Toulouse. Boehringer has also agreed to pay particular attention to sustaining the momentum of operations in the US, an important market for the Merial business.

For Sanofi’s future CHC business, Germany will be a key center, focusing on gastrointestinal and cough & cold categories in particular. The company said it expects the overall transaction to be accretive to earnings from 2018. The deal, originally announced in December 2015, is expected to close by the end of 2016, subject to regulatory approvals.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.